ProSciento’s Board members have been at the forefront of metabolic drug development, clinical research and capital investment in the healthcare industry.
Marcus Hompesch, M.D.
Chief Executive Officer and Chairman of the Board at ProSciento, Inc.
Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO
Partner at 1315 Capital, LLC